Aemetis (NASDAQ:AMTX) Posts Earnings Results, Misses Expectations By $0.12 EPS

Aemetis (NASDAQ:AMTX - Get Free Report) announced its earnings results on Thursday. The specialty chemicals company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.12), Zacks reports. The firm had revenue of $59.19 million during the quarter, compared to analyst estimates of $87.79 million.Aemetis Trading Up 19.3%AMTX stock traded up $0.34 during midday trading on Friday, reaching $2.10. The stock had a trading volume of 1,324,071 shares, compared to its average volume of 999,169. Aemetis has a 52-week low of $1.22 and a 52-week high of $4.73. The company's fifty day simple moving average is $2.46 and its 200 day simple moving average is $2.31. The company has a market cap of $132.81 million, a price-to-earnings ratio of -1.30 and a beta of 1.73. Wall Street Analysts Forecast GrowthSeveral equities research analysts recently commented on AMTX shares. Ascendiant Capital Markets boosted their price target on shares of Aemetis from $20.00 to $21.00 and gave the stock a "buy" rating in a report on Monday, October 6th. Weiss Ratings reissued a "sell (e+)" rating on shares of Aemetis in a research note on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Aemetis presently has a consensus rating of "Moderate Buy" and a consensus price target of $17.33.Get Our Latest Stock Analysis on AemetisInsider Activity at AemetisIn other news, Director Francis P. Barton sold 26,452 shares of the firm's stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $2.53, for a total value of $66,923.56. Following the transaction, the director directly owned 208,518 shares of the company's stock, valued at approximately $527,550.54. This trade represents a 11.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 14.70% of the stock is owned by company insiders. Institutional Inflows and OutflowsA number of institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its position in shares of Aemetis by 15.3% during the 3rd quarter. Vanguard Group Inc. now owns 2,479,163 shares of the specialty chemicals company's stock valued at $5,578,000 after acquiring an additional 329,760 shares during the last quarter. Jane Street Group LLC acquired a new stake in Aemetis during the second quarter worth about $634,000. Qube Research & Technologies Ltd purchased a new position in Aemetis during the second quarter worth about $246,000. Jump Financial LLC purchased a new position in Aemetis during the second quarter worth about $64,000. Finally, Russell Investments Group Ltd. boosted its holdings in Aemetis by 412.9% in the 2nd quarter. Russell Investments Group Ltd. now owns 80,754 shares of the specialty chemicals company's stock valued at $200,000 after purchasing an additional 65,010 shares during the last quarter. 27.02% of the stock is owned by hedge funds and other institutional investors. About Aemetis (Get Free Report)Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.See AlsoFive stocks we like better than AemetisWhat is MarketRank™? How to Use itOpenAI's Restructuring Sets up What Could Be the Biggest IPO EverWhat Does a Gap Up Mean in Stocks? How to Play the Gap2 Rare Earth Stocks the U.S. Government Doesn’t Want to FailUsing the MarketBeat Dividend Yield CalculatorCrowdStrike Partners With CoreWeave But Investors Sell the NewsThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Aemetis Right Now?Before you consider Aemetis, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aemetis wasn't on the list.While Aemetis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here